Protara Therapeutics Inc
TARA
Get informed when a big investor buys or sells
+ FollowMarket Cap$231.56M
Close$
$1.08
72.6% downside
Current Fair Value
72.6% downsideOvervalued by 72.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $231.56 Million |
|---|---|
| Enterprise Value | $219.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.34 |
| Beta | 1.48 |
| Outstanding Shares | 42,836,129 |
Return
| Return on Equity | -34.94% |
|---|---|
| Return on Assets | -32.99% |
| Return on Invested Capital | -36.69% |
Valuation & Multiples
| P/E Ratio | -2.82 |
|---|---|
| PEG | -5.73 |
| Price to Sales | - |
| Price to Book Ratio | 0.99 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.27 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$180,000
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
$180,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 24.29% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.31%▼ 92.05% |
|---|---|
| Total Invested | $23.42M▼ 90.13% |
| Investors Holding | 33▼ 85.00% |
ESG Score
No data
About Protara Therapeutics Inc
CEO: Jesse Shefferman